Dataset from A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose Response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.

The purpose of this study is to determine the effectiveness, safety, and tolerability (how well the body stands the drug) of an investigational protease inhibitor (PI) called TMC114 given with low dose ritonavir.

本研究旨在明确研究性蛋白酶抑制剂（protease inhibitor，PI）TMC114联合低剂量利托那韦给药时的有效性、安全性及耐受性（机体对该药物的耐受程度）。